The stock of Inflarx N.V. (NASDAQ:IFRX) registered an increase of 17.35% in short interest. IFRX’s total short interest was 443,000 shares in April as published by FINRA. Its up 17.35% from 377,500 shares, reported previously. With 109,000 shares average volume, it will take short sellers 4 days to cover their IFRX’s short positions. The short interest to Inflarx N.V.’s float is 6.21%.
The stock decreased 2.84% or $1.19 during the last trading session, reaching $40.72. About 299,912 shares traded or 117.79% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 39.39% since April 8, 2018 and is uptrending. It has outperformed by 35.02% the S&P500.
InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $1.06 billion. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.
– Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Globenewswire.com which released: “InflaRx N.V. To Host R&D Day on Hidradenitis Suppurativa and its Breakthrough Anti-C5a Monoclonal Antibody IFX-1 – GlobeNewswire” on August 28, 2018, also Seekingalpha.com with their article: “InflaRx Update: Pipeline Continues To Progress, Data In 1H 2019 – Seeking Alpha” published on November 24, 2018, Globenewswire.com published: “InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate IFX-1 in Pyoderma Gangraenosum – GlobeNewswire” on February 27, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Globenewswire.com and their article: “InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management – GlobeNewswire” published on January 03, 2019 as well as Globenewswire.com‘s news article titled: “Richard Brudnick to Join InflaRx Board of Directors – GlobeNewswire” with publication date: February 14, 2019.